Health care is a vulnerabilityfor the president entering his re-election, and his budget proposalreleased Monday projects billions in unspecified drug-costsavings.

(Bloomberg) –President Donald Trump is considering executiveaction to cut drug prices ahead of the 2020 election, officialsfamiliar with the matter say, as he enters his re-election seekingto rebut Democratic criticism that his policies have hurt U.S.health care.

If he proceeds, Trump would force drug companies to accept lowerpayments from Medicare for treatments administered in doctors'offices, such as Bristol-Myers Squibb Co.'s immune-boosting Opdivofor cancer and Regeneron Pharmaceuticals Inc.'s Eylea for eyeconditions. The rule would apply to certain drugs bought by the"Part B" section of Medicare, the program for the elderly anddisabled.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.